Trial Profile
Efficacy and safety of bortezomib + thalidomide + dexamethasone (VTd) as consolidation therapy in patients with newly diagnosed multiple myeloma that reached PR at completion of VTd induction
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Feb 2014
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone; Thalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 13 Feb 2014 New trial record
- 10 Dec 2013 Results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.